CONMED Reports Q3 2026 Results with Organic Revenue Growth Driven by International Markets
CONMED Corporation (CNMD) reported third-quarter results featuring a 6.7% organic constant currency revenue growth, despite a slight reported net revenue decrease to $335.6 million due to the strategic exit from gastroenterology product lines. The company's performance was bolstered by strong international expansion in both General Surgery and Orthopedic segments, with international sales growing significantly in EMEA and APAC regions. While domestic orthopedic sales saw a 1.7% decline following commercial reorganization, adjusted diluted EPS of $1.04 exceeded management expectations. Looking ahead, CONMED raised its full-year adjusted EPS guidance to a range of $4.54 to $4.61, though it narrowed its organic sales growth guidance to 5%–5.5% after noting that previous fourth-quarter projections were overly optimistic.
Topics: EPS Beat Free Cash Flow Operating Margin Organic Revenue Revenue Growth
Read the full article at Motley Fool
Part of the story Freedom Financial Holdings Reports Q3 2026 Earnings Growth and Increases Share Repurchase Authorization (27 articles)